Circulating inflammatory cytokines in relation to the risk of renal cell carcinoma: A gender-specific two-sample Mendelian randomization study.
Eotaxin
Mendelian randomization
cytokines
renal cell carcinoma
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
09
09
2023
received:
12
05
2023
accepted:
29
09
2023
pubmed:
30
10
2023
medline:
30
10
2023
entrez:
30
10
2023
Statut:
ppublish
Résumé
Currently there is no specific molecular biomarker for the diagnosis and treatment of renal cell carcinoma (RCC). Here we performed a gender-specific two-sample Mendelian randomization analysis to systematically assess the effects of circulating cytokines on RCC. We have employed cis-quantitative trait loci as instrumental variables for the protein levels and expression of circulating cytokines. We estimated the causal effects of circulating cytokines on RCC risk in males and females with several Mendelian randomization methods. We observed a significant causal effect of Eotaxin on the increased risk of RCC in males (Odds ratio [OR] = 2.546, 95% confidence interval [CI] = 1.617-4.010, p value = 5.496 × 10-5), but not in females (OR = 1.352, 95% CI = 0.766-2.388, p value = 0.298). Besides, we also identified several cytokines as potentially associated with RCC in males including RANTES, MCP3, PDGFbb, TRAIL, and several other cytokines as potentially associated with RCC in females including sICAM and SCGFb. Our study highlighted that a higher level of circulating Eotaxin is causally associated with an increased risk of RCC in males but not in females. Further studies are needed to elucidate the exact mechanism and its potential application in the prognosis and treatment of RCC.
Sections du résumé
BACKGROUND
BACKGROUND
Currently there is no specific molecular biomarker for the diagnosis and treatment of renal cell carcinoma (RCC). Here we performed a gender-specific two-sample Mendelian randomization analysis to systematically assess the effects of circulating cytokines on RCC.
METHODS
METHODS
We have employed cis-quantitative trait loci as instrumental variables for the protein levels and expression of circulating cytokines. We estimated the causal effects of circulating cytokines on RCC risk in males and females with several Mendelian randomization methods.
RESULTS
RESULTS
We observed a significant causal effect of Eotaxin on the increased risk of RCC in males (Odds ratio [OR] = 2.546, 95% confidence interval [CI] = 1.617-4.010, p value = 5.496 × 10-5), but not in females (OR = 1.352, 95% CI = 0.766-2.388, p value = 0.298). Besides, we also identified several cytokines as potentially associated with RCC in males including RANTES, MCP3, PDGFbb, TRAIL, and several other cytokines as potentially associated with RCC in females including sICAM and SCGFb.
CONCLUSION
CONCLUSIONS
Our study highlighted that a higher level of circulating Eotaxin is causally associated with an increased risk of RCC in males but not in females. Further studies are needed to elucidate the exact mechanism and its potential application in the prognosis and treatment of RCC.
Identifiants
pubmed: 37902279
doi: 10.1002/cam4.6658
pmc: PMC10709742
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21013-21021Subventions
Organisme : Zhejiang Medical and Health Science and Technology Project
ID : 2023XY070
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Oncol Rep. 2014 May;31(5):2049-54
pubmed: 24604010
Adv Exp Med Biol. 2022;1374:63-72
pubmed: 35038147
Lancet Oncol. 2012 May;13(5):518-27
pubmed: 22440112
Elife. 2018 May 30;7:
pubmed: 29846171
Eur Urol. 2022 Nov;82(5):529-542
pubmed: 36100483
Radiol Clin North Am. 2017 Nov;55(6):1235-1250
pubmed: 28991563
Int J Epidemiol. 2017 Dec 1;46(6):1734-1739
pubmed: 28398548
Int J Cancer. 2020 Nov 1;147(9):2469-2478
pubmed: 33460126
Cancer Med. 2023 Nov;12(22):21013-21021
pubmed: 37902279
Eur Urol. 2015 Mar;67(3):519-30
pubmed: 25449206
Front Oncol. 2020 Feb 05;9:1555
pubmed: 32117786
Int J Mol Sci. 2020 May 10;21(9):
pubmed: 32397685
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Nat Rev Methods Primers. 2022 Feb 10;2:
pubmed: 37325194
Nat Commun. 2017 Jun 09;8:15724
pubmed: 28598434
Blood. 2003 Feb 15;101(4):1487-93
pubmed: 12393570
Epidemiology. 2004 Jan;15(1):93-9
pubmed: 14712152
Genet Epidemiol. 2016 May;40(4):304-14
pubmed: 27061298
Br J Cancer. 2019 Jan;120(1):6-15
pubmed: 30413827
NPJ Precis Oncol. 2020 Sep 1;4:25
pubmed: 32923685
J Med Genet. 2019 Sep;56(9):607-616
pubmed: 31217265
Clin Cancer Res. 2005 Apr 1;11(7):2459-65
pubmed: 15814620
Nature. 2018 Jun;558(7708):73-79
pubmed: 29875488
Sci Rep. 2022 Aug 4;12(1):13416
pubmed: 35927313
Eur J Epidemiol. 2017 May;32(5):377-389
pubmed: 28527048
Nat Rev Urol. 2019 Sep;16(9):539-552
pubmed: 31278395
Eur J Hum Genet. 2019 Oct;27(10):1589-1598
pubmed: 31231134
Oncogene. 2021 Nov;40(47):6540-6546
pubmed: 34625710
Nat Rev Clin Oncol. 2022 Apr;19(4):237-253
pubmed: 34997230
BMC Med. 2022 Jan 11;20(1):3
pubmed: 35012533
Oral Dis. 2003 Nov;9(6):279-83
pubmed: 14629326
Nat Metab. 2020 Oct;2(10):1135-1148
pubmed: 33067605
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
Cold Spring Harb Perspect Med. 2022 May 17;12(4):
pubmed: 34872952
G Ital Nefrol. 2022 Jun 20;39(3):
pubmed: 35819037